GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Trevi Therapeutics
Trevi Therapeutics is a biotech company developing a drug to treat chronic cough and itching. Its stock price is highly volatile and depends on clinical trial results. The chart reflects investor expectations for success in these difficult-to-treat conditions.
Share prices of companies in the market segment - Neuro
Trevi is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. We classify it in the Neuro sector, and the chart below reflects the dynamics of this entire segment, driven by news about clinical trials and regulatory decisions.
Broad Market Index - GURU.Markets
Trevi Therapeutics is a biopharmaceutical company developing treatments for chronic cough and other neurological diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Trevi shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TRVI - Daily change in the company's share price Trevi Therapeutics
Change_co for Trevi Therapeutics, a biopharmaceutical company, reflects extreme volatility associated with clinical trial results. Daily fluctuations indicate sensitivity to news about the company's drug development. This metric is important for biotech risk analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Trevi Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TRVI, which focuses on chronic cough treatment, helps to assess it as a high-risk, data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Trevi is a biopharmaceutical company developing drugs to treat neurological diseases. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Trevi's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Trevi Therapeutics
Trevi is a biopharmaceutical company working on treatments for neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Annual dynamics of market capitalization of the market segment - Neuro
Trevi Therapeutics, Inc. is a clinical-stage biotech developing drugs for the treatment of chronic cough and itching. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in these areas of unmet need.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Trevi Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Trevi Therapeutics
Trevi, a biopharmaceutical company specializing in the treatment of chronic cough and itching, has monthly fluctuations reflecting news about clinical trials of its lead drug, which is typical for biotech companies in the R&D stage.
Monthly dynamics of market capitalization of the market segment - Neuro
Developing drugs to treat neurological diseases is one of the most complex areas of biotechnology. The dynamics of this sector, reflected in the chart, demonstrate high volatility and dependence on clinical trial results. Companies like Trevi Therapeutics operate in this risky environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Trevi Therapeutics develops drugs for the treatment of neurological diseases. Like many biotech companies, its shares move in sync with clinical trial news. Their performance is completely disconnected from the broader market and is a bet on scientific success.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Trevi Therapeutics
Trevi Therapeutics, a biopharmaceutical company focused on treating chronic cough, experiences extremely volatile weekly performance. News about clinical trials, FDA decisions, or drug efficacy data can cause sharp and significant price fluctuations.
Weekly dynamics of market capitalization of the market segment - Neuro
Trevi Therapeutics and the entire clinical-stage biotech sector are a zone of extreme volatility driven by overall investor sentiment. The success of one company can boost interest in the entire niche. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Trevi Therapeutics shares, like many biotechs, often move independently of the broader market. Their weekly performance is driven by clinical trial news rather than macroeconomics. The chart shows moments when the company's shares completely defied the overall market trend.
Market capitalization of the company, segment and market as a whole
TRVI - Market capitalization of the company Trevi Therapeutics
Trevi Therapeutics' market capitalization is the financial valuation of a biotech company focused on treating chronic cough and itching. The chart reflects investor expectations for its lead drug, Haduvio. Its dynamics tell the story of how the market evaluates the potential for solving problems that significantly reduce the quality of life for millions of patients.
TRVI - Share of the company's market capitalization Trevi Therapeutics within the market segment - Neuro
Trevi Therapeutics is developing a drug to treat chronic itching associated with various conditions. Its market share in the biotech sector is based on this unmet medical need. The chart shows how the market views the potential of its lead candidate to become the first approved treatment for this condition.
Market capitalization of the market segment - Neuro
Trevi Therapeutics is working on treating chronic cough and itching. The chart below shows the overall market capitalization of the neuroscience sector. It reflects the search for solutions to debilitating conditions that impact quality of life. In this niche, Trevi aims to offer a first-of-its-kind treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies visible in the chart are seeking solutions to complex neurological problems. Trevi Therapeutics is developing a drug to treat chronic itching associated with various conditions. Its capitalization is a risky bet that its drug will help patients with this debilitating symptom.
Book value capitalization of the company, segment and market as a whole
TRVI - Book value capitalization of the company Trevi Therapeutics
Trevi Therapeutics's schedule represents capital for solving the problem of chronic cough and itching. The company's book value at the R&D stage consists of financial reserves. These assets are being used to conduct clinical trials of its lead drug, which targets neural pathways.
TRVI - Share of the company's book capitalization Trevi Therapeutics within the market segment - Neuro
Trevi Therapeutics, a clinical-stage biopharmaceutical company, holds minimal tangible assets in the sector, consisting of offices and laboratories. The chart shows that its primary value is currently concentrated in intellectual property and clinical trial data.
Market segment balance sheet capitalization - Neuro
Trevi Therapeutics is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Trevi focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. Its book value is the capital it is investing in clinical trials of its lead candidate, Haduvio.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company. Its market capitalization is close to its book value (primarily cash), suggesting the market has not yet priced in a high probability of clinical trial success.
Market to book capitalization ratio in a market segment - Neuro
Trevi Therapeutics develops drugs to treat neurological diseases characterized by itching. Like many biotech companies, its value is determined by the potential of its lead drug. The chart shows the premium investors place on scientific developments compared to the book value of its assets.
Market to book capitalization ratio for the market as a whole
Trevi Therapeutics is a biopharmaceutical company developing a drug for the treatment of chronic cough and itching. Compared to average market valuations, as shown in this chart, its valuation is highly volatile and depends entirely on clinical trial results and regulatory decisions regarding its only lead candidate.
Debts of the company, segment and market as a whole
TRVI - Company debts Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat neurological diseases characterized by itching. Currently in clinical trials, the company has no stable revenue and requires external funding. This chart shows how the company raises capital to support the expensive research and development of its drug candidates.
Market segment debts - Neuro
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurological diseases. Like other companies of this type, it has no sales revenue and relies entirely on external funding for its research. This chart reflects its financial health and ability to continue clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company focused on treating neurological diseases. This chart shows how dependent it is on debt financing. For a company in clinical development without stable revenue, debt is a serious risk that could lead to a shortage of research funds if one stage fails.
Market segment debt to market segment book capitalization - Neuro
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. Clinical trials in this field are complex and require significant funding. This chart shows the overall debt burden in the biotech sector, providing context for understanding Trevi's financial strategy as it moves toward commercialization.
Debt to book value of all companies in the market
Trevi Therapeutics is a biopharmaceutical company developing drugs for neurological diseases. During the clinical trial stage, funding is key. This chart provides insight into the overall cost of capital, helping to understand why companies at this stage often avoid debt, preferring partnerships or additional equity issuances.
P/E of the company, segment and market as a whole
P/E - Trevi Therapeutics
For Trevi Therapeutics, a clinical-stage biopharmaceutical company, P/E is not a relevant metric. The company has no revenue or profit, so any values on this chart are purely arbitrary. Trevi's valuation is based solely on investors' faith in the scientific potential of its experimental drugs.
P/E of the market segment - Neuro
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio for the treatment of chronic cough and itching. This chart shows the average valuation for the biotech sector. It allows investors to assess the market's perception of the potential success of a niche drug targeting conditions with unmet medical needs.
P/E of the market as a whole
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat chronic cough and itching. Its valuation is entirely dependent on the success of clinical trials. Overall market sentiment, reflected in this chart, is irrelevant. Trevi's fate is decided by clinical data reports, not inflation or GDP figures.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing treatments for chronic cough and itching. The company's potential lies in solving problems affecting millions of people. This chart reflects investor expectations regarding the success of clinical trials and future commercial demand for its drugs, which forms the basis for its revenue forecasts.
%20P%2FE%20Trevi%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Trevi-Therapeutics&v=1772632831998 "Chart of the company's future (projected) P/E Trevi Therapeutics")
Future (projected) P/E of the market segment - Neuro
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a drug to treat chronic cough and itching. This chart shows general profitability expectations for the biotech sector. TRVI's position relative to the average reflects investors' confidence in the success of its clinical trials and the drug's potential to address these common medical conditions.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772632832000 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Trevi Therapeutics is a biopharmaceutical company working on treatments for neurological diseases. Like many in the sector, it relies on clinical trial results. This chart of overall market sentiment is important because it impacts the cost of capital. Market optimism makes funding for expensive research cheaper.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632832080 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of chronic itching and cough. Its financials currently reflect a net loss due to high clinical trial costs. Future profitability depends on the approval and successful launch of its drug.
Profit of companies in the market segment - Neuro
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat neurological diseases characterized by chronic itching and cough. Its prospects are pinned on successful clinical trials. This chart shows the total revenue for its sector, illustrating the level of investor confidence in the commercial potential of its developments for the treatment of complex neurological conditions.
Overall market profit
Trevi Therapeutics develops drugs for neurological diseases, a long and expensive process. Access to funding is critical for such companies. When overall market revenues rise, as in this graph, the investment climate improves. This allows Trevi to raise funds for clinical trials, which are crucial to the company's future.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat chronic cough and itching. Future revenue depends on the success of clinical trials and approval of its lead candidate. This chart shows analyst forecasts, which represent their assessment of the likelihood of commercial success for the drug in treating these debilitating conditions.
%20profit%20of%20the%20company%20Trevi%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Trevi-Therapeutics&v=1772632832143 "Graph of future (projected) profit of the company Trevi Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Trevi Therapeutics develops drugs to treat chronic cough and other neurological conditions. The company's future depends on the results of clinical trials and the need for new treatments for these common conditions. This chart reflects profitability forecasts for the entire pharmaceutical sector, providing context for assessing Trevi's potential in its niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772632832166 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Trevi Therapeutics is a biopharmaceutical company working on treatments for neurological diseases. Like other clinical-stage companies in this sector, its prospects depend on research success rather than macroeconomic indicators. This total revenue chart is largely irrelevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632832214 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases, such as chronic cough. Being in clinical trials, it has limited revenue. The chart shows the market's assessment of its scientific potential and the chances of commercializing its lead drug candidate.
P/S market segment - Neuro
Trevi Therapeutics is a biopharmaceutical company developing treatments for chronic cough and itching. Future revenue depends on the success of clinical trials. This pharmaceutical sector chart provides insight into investor expectations regarding the potential of Trevi's drugs to address conditions affecting millions of patients and lacking effective treatment.
P/S of the market as a whole
Trevi Therapeutics is a biopharmaceutical company developing a drug to treat chronic pruritus associated with various medical conditions. This condition significantly reduces quality of life, and effective treatments are few. This earnings valuation chart helps understand how investors value the company's potential to address an unmet medical need.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat severe itching associated with various conditions. This chart shows how the market views the future commercial potential of its lead candidate. It reflects investors' confidence that the drug will successfully complete clinical trials and find its niche in the market.
%20P%2FS%20Trevi%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Trevi-Therapeutics&v=1772632832310 "The graph of the company's future (projected) P/S Trevi Therapeutics")
Future (projected) P/S of the market segment - Neuro
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a treatment for chronic pruritus associated with various conditions. The company's valuation reflects investor expectations regarding the potential of its lead candidate to address this significant unmet medical need, which is associated with high clinical risks.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772632832312 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Trevi Therapeutics is a biopharmaceutical company working on the treatment of chronic cough and itching. Its success depends on the results of clinical trials. In the overall revenue growth picture illustrated by the chart, Trevi represents an innovative biotech company targeting unmet medical needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632832316 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases characterized by itching and cough. Being in the clinical stage, the company has no commercial revenue from product sales. Any revenue reflected in the chart likely comes from licensing agreements or grants.
Sales of companies in the market segment - Neuro
Trevi Therapeutics (TRVI) is a biopharmaceutical company developing Haduvio for the treatment of chronic cough and itching associated with neurological diseases. These conditions significantly reduce quality of life. This chart shows revenue from the neurological segment, where Trevi is targeting unmet medical needs with significant market potential.
Overall market sales
Trevi Therapeutics develops drugs to treat neurological diseases characterized by chronic itching or coughing. While the need for treatments is not dependent on the economy, the financial environment does. This graph, reflecting the overall market situation, impacts Trevi's ability to raise capital for costly clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biotech company developing a drug for the treatment of chronic cough and itching. Future revenue depends on the success of clinical trials and the commercialization of its lead candidate. This chart shows analyst forecasts, which estimate the likelihood of success and potential market demand for their therapy.
%20sales%20of%20the%20company%20Trevi%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Trevi-Therapeutics&v=1772632832361 "Schedule of future (projected) sales of the company Trevi Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Trevi Therapeutics is a biopharmaceutical company developing treatments for chronic cough and itching. This graph shows the potential future revenue of their lead candidate, Haduvio. This is an analyst's view of the commercial prospects of this drug for conditions for which there are currently few effective therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772632832377 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Trevi Therapeutics is a biopharmaceutical company developing a drug for the treatment of chronic cough and itching. The company's success depends on the results of clinical trials and regulatory approval. This graph, reflecting the overall economic situation, influences the investment climate in the biotech sector and the pricing of new drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632832417 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Trevi Therapeutics
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. Being in clinical development, the company incurs significant research expenses. The chart shows the current financial picture, where the profitability is negative due to investments that could yield significant returns if the drugs are successful.
Market segment marginality - Neuro
Trevi Therapeutics is a biopharmaceutical company developing Haduvio for the treatment of chronic itching and cough. This chart reflects its operating expenses during the clinical trial phase. The company's success and future profitability are entirely dependent on positive trial results and subsequent regulatory approval.
Market marginality as a whole
Trevi Therapeutics develops drugs for the treatment of neurological diseases. Like other development-stage biotech companies, it relies on external funding. This total return chart reflects the market's willingness to invest in risky assets. Economic recovery and high margins create favorable conditions for raising funds for clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a therapy for chronic cough. Its small team is focused on conducting clinical trials. The growth of its staff on this schedule will signal a transition to later, larger-scale research phases, which require more specialists.
Share of the company's employees Trevi Therapeutics within the market segment - Neuro
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious neurological conditions. The size of its team directly reflects the intensity and scale of its clinical research. This chart illustrates the human capital the company is investing in finding solutions for complex and debilitating diseases.
Number of employees in the market segment - Neuro
Trevi Therapeutics develops drugs to treat neurological diseases associated with itching. The employment trends in the neuroscience sector, reflected here, demonstrate the scale of investment in brain research. For Trevi, the growing number of scientists and clinicians means accelerating research in their niche, which could facilitate both new discoveries and the emergence of competitive developments.
Number of employees in the market as a whole
Trevi Therapeutics is a biopharmaceutical company focused on neurological diseases. Its expansion is driven by successful clinical trials and funding, rather than the business cycle. It recruits highly specialized medical and research professionals from the broader talent pool depicted in this chart.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Trevi Therapeutics (TRVI)
Trevi Therapeutics is a biopharmaceutical company developing a drug to treat chronic cough and itching. Its business is entirely dependent on the success of clinical trials. This metric reflects how the market perceives the potential of a single drug to solve a major medical problem. A high value indicates investor confidence in a potential blockbuster.
%20of%20the%20company%20Trevi%20Therapeutics%20(TRVI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Trevi-Therapeutics-TRVI&v=1772632832726 "Chart of market capitalization per employee (in thousands of dollars) of the company Trevi Therapeutics (TRVI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Trevi Therapeutics develops drugs for the treatment of neurological diseases. In biotech, market capitalization reflects clinical research potential. This chart shows the value investors place on a company's intellectual property and research per employee working on new drug development.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772632832831 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurological diseases. The chart shows an assessment of its scientific potential. The company's value is based on expectations for clinical trials. This indicator reflects the value investors place on the work of each scientist seeking solutions to complex diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632832877 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Trevi Therapeutics (TRVI)
Trevi Therapeutics is a biotech company developing drugs to treat chronic cough and itching. The company is in clinical trials. This graph likely shows negative profit per employee, which is typical for the R&D sector. It reflects the investment the company makes in each employee to bring the drug to market.
%20Chart%20Trevi%20Therapeutics%20(TRVI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Trevi-Therapeutics-TRVI&v=1772632832892 "Company Profit Per Employee (in thousands of dollars) Chart Trevi Therapeutics (TRVI)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Trevi Therapeutics is a biopharmaceutical company developing drugs to treat chronic cough and itching. The company is in late-stage R&D and preparing for commercialization. This metric is likely still negative, but investors are monitoring it in anticipation of a tipping point when sales revenue begins to cover personnel costs.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772632833017 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. The company is in clinical trials. Like other biotechs (Sionna, ORIC), its business is purely R&D. Its profit per employee is negative. This chart is important for context: in this industry, value is created not by current revenue, but by research progress that can lead to drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632833061 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Trevi Therapeutics (TRVI)
Trevi Therapeutics is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. Being in the clinical stage, it has not yet generated commercial revenue. This chart shows the minimum values, which is typical for companies whose activities are focused on clinical trials and regulatory approval.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Trevi-Therapeutics-TRVI&v=1772632833081 "Sales chart per company employee Trevi Therapeutics (TRVI)")
Sales per employee in the market segment - Neuro
Trevi Therapeutics (TRVI) is a biopharmaceutical company developing drugs for the treatment of chronic cough and itching. This metric reflects the average revenue per employee in the segment. For a company in the development stage, it is important for assessing capital efficiency and comparing its workforce structure with other biotech companies.
Sales per employee for the market as a whole
Trevi Therapeutics (TRVI) is a biopharmaceutical company developing therapies for the treatment of chronic cough and itching associated with neurological diseases. This metric represents the current cost of research per scientist, pending commercialization of their drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Trevi Therapeutics (TRVI)
Trevi Therapeutics (TRVI) is a biotech company developing drugs to treat chronic cough and itching, conditions with unmet medical needs. This chart shows the level of skepticism. An increase in short positions signals that investors are unsure of the company's clinical trials or doubt the potential market size for its lead candidate. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Trevi-Therapeutics-TRVI&v=1772632833121 "Short Shares Chart for the Company Trevi Therapeutics (TRVI)")
Shares shorted by market segment - Neuro
Trevi Therapeutics is developing a drug to treat chronic cough and itching associated with neurological conditions. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotech companies working in complex neurological fields.
Shares shorted by the overall market
Trevi Therapeutics is a biotech company whose fate depends on the success of clinical trials. This is a speculative bet. When this indicator of overall pessimism rises, investors are unwilling to take risks. They are dumping unprofitable biotechs without stable cash flow, and TRVI shares are caught in this wave of sell-offs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Trevi Therapeutics (TRVI)
Trevi Therapeutics (TRVI) is a biopharmaceutical company developing Haduvio for the treatment of chronic cough and itching associated with neurological diseases. This chart measures hype. It indicates "overbought" (above 70) on positive clinical trial data or "oversold" (below 30) on news of R&D delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Trevi-Therapeutics-TRVI&v=1772632833167 "RSI 14 indicator chart for the company's stock Trevi Therapeutics (TRVI)")
RSI 14 Market Segment - Neuro
Trevi Therapeutics (TRVI) is a biopharmaceutical company developing a treatment for chronic pruritus associated with various conditions. This chart measures the pulse of the Neuroscience/Pharma sector. It helps distinguish Trevi's clinical trial successes from the overall "overheating" or "overselling" of the entire biotech sector.
RSI 14 for the overall market
Trevi Therapeutics (TRVI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TRVI (Trevi Therapeutics)
Trevi Therapeutics is a biopharmaceutical company developing a drug (Hadjove) for the treatment of chronic pruritus associated with various systemic diseases. This chart displays the average analyst estimate, showing their collective price target for TRVI shares.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TRVI-Trevi-Therapeutics&v=1772632833207 "A chart showing analyst consensus forecasts for the expected stock price. TRVI (Trevi Therapeutics)")
The difference between the consensus estimate and the actual stock price TRVI (Trevi Therapeutics)
Trevi Therapeutics is a clinical-stage biotech developing a drug (Nalbuphine ER) for the treatment of chronic pruritus associated with various conditions. This chart reflects analyst expectations for their clinical trials and the size of this underserved market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TRVI-Trevi-Therapeutics&v=1772632833209 "A chart showing the difference between the consensus forecast and the actual stock price. TRVI (Trevi Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Trevi Therapeutics is a biotech company developing Haduvio for the treatment of chronic cough and itching, conditions associated with neurological disorders. This chart shows analysts' overall expectations for the neurology sector, reflecting their belief in the market's potential.
Analysts' consensus forecast for the overall market share price
Trevi Therapeutics is a biopharmaceutical company developing a drug to treat chronic cough and itching associated with neurological diseases. This chart shows overall risk appetite. For Trevi, a company with a niche focus, overall market optimism is important for attracting investor attention and funding clinical trials in these challenging areas.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Trevi Therapeutics
Trevi Therapeutics is a biotech company focused on treating chronic, intractable cough and itching associated with neurological diseases. Their lead candidate (Haduvio) targets these debilitating conditions for which effective treatments are scarce. This chart is an assessment of their R&D pipeline and reflects investor expectations for clinical data on their key drug.
AKIMA Market Segment Index - Neuro
Trevi (TRVI) is a clinical-stage biotech focused on neuroscience; the company is developing its candidate (Haduvio) for the treatment of chronic itching and chronic cough. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (itching/cough) R&D rate (TRVI) differentiate it from the average pharma company?
The AKIM Index for the overall market
Trevi Therapeutics is a biopharmaceutical company developing a therapy (Haduvio) for the treatment of chronic cough and prurigo (itching). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical trial, aimed at improving patients' quality of life, compares to overall economic trends.
